IL-25 Promotes Cisplatin Resistance of Lung Cancer Cells by Activating NF-κB Signaling Pathway to Increase of Major Vault Protein

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 May 3

PMID 31044552

Citations 13

Authors

Weiming Shen

Yang Qiu

Jingyao Li

Chao Wu

Zhihui Liu

Xiaorong Zhang

Xiaohong Hu

Yi Liao

Haidong Wang

Affiliations

Soon will be listed here.

Abstract

As an inflammatory factor, IL-25 has been studied in variouscancers, but it is rarely reported in cancer chemotherapy resistance. Major vault protein (MVP), as a gene associated with lung multidrug resistance, is associated with multiple chemotherapy resistances of lung cancer. However, the relationship between IL-25 and MVP in lung cancer cells has not been studied. In this study, we found that both IL-25 and MVP were elevated expressed in cisplatin-resistant lung adenocarcinoma cell line (A549/CDDP). Silencing of IL-25 resulted in down-regulation of MVP expression and reduced cisplatin tolerance of A549/CDDP cells. Overexpression of IL-25 resulted in increase of MVP expression and the cisplatin tolerance in A549 cells. In addition, we found that the extracellular IL-25 could stimulate the expression of MVP and activate the NF-κB signaling pathway. Further, animal models also confirmed that IL-25 reduced the sensitivity of xenografts to chemotherapy. Taken together, we believe that the up-regulation of IL-25 induces MVP expression contributing to chemotherapy resistances of lung cancer cells. Our findings suggest that interference the expression of IL-25 might be potential treatment strategies for the clinical reversing the chemotherapy resistance.

Citing Articles

Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications.

Maniatis A, Rizopoulou D, Shaukat A, Grafanaki K, Stamatopoulou V, Stathopoulos C Int J Mol Sci. 2025; 26(4).

PMID: 40004027 PMC: 11855390. DOI: 10.3390/ijms26041562.

Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer.

Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M Mol Biomed. 2025; 6(1):2.

PMID: 39757310 PMC: 11700966. DOI: 10.1186/s43556-024-00239-2.

The prognostic value and immunological role of MVP in pan-cancer study.

Li C, Gao M, Zha N, Guo G Aging (Albany NY). 2024; 16(10):8497-8510.

PMID: 38713157 PMC: 11164508. DOI: 10.18632/aging.205802.

Crosstalk between vault RNAs and innate immunity.

Avila-Bonilla R, Martinez-Montero J Mol Biol Rep. 2024; 51(1):387.

PMID: 38443657 PMC: 10914904. DOI: 10.1007/s11033-024-09305-y.

MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers.

Tolue Ghasaban F, Maharati A, Zangouei A, Zangooie A, Moghbeli M Cancer Cell Int. 2023; 23(1):170.

PMID: 37587481 PMC: 10428558. DOI: 10.1186/s12935-023-03010-9.

References

Aggarwal S, Gurney A . IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002; 71(1):1-8. View

Suprenant K . Vault ribonucleoprotein particles: sarcophagi, gondolas, or safety deposit boxes?. Biochemistry. 2002; 41(49):14447-54. DOI: 10.1021/bi026747e. View

Herrmann C, Golkaramnay E, Inman E, Rome L, Volknandt W . Recombinant major vault protein is targeted to neuritic tips of PC12 cells. J Cell Biol. 1999; 144(6):1163-72. PMC: 2150576. DOI: 10.1083/jcb.144.6.1163. View

Scheffer G, Wijngaard P, Flens M, Izquierdo M, Slovak M, Pinedo H . The drug resistance-related protein LRP is the human major vault protein. Nat Med. 1995; 1(6):578-82. DOI: 10.1038/nm0695-578. View

Wu H, Hwang-Verslues W, Lee W, Huang C, Wei P, Chen C . Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med. 2015; 212(3):333-49. PMC: 4354366. DOI: 10.1084/jem.20141702. View

Lv Q, Wu K, Liu F, Wu W, Chen Y, Zhang W . Interleukin‑17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer. Int J Oncol. 2018; 53(4):1809-1817. DOI: 10.3892/ijo.2018.4503. View

Kedersha N, Miquel M, Bittner D, Rome L . Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Cell Biol. 1990; 110(4):895-901. PMC: 2116106. DOI: 10.1083/jcb.110.4.895. View

Xiao L, Lan X, Shi X, Zhao K, Wang D, Wang X . Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer. Cell Death Dis. 2017; 8(5):e2803. PMC: 5520727. DOI: 10.1038/cddis.2017.210. View

He J, Zhao J, Peng X, Shi X, Zong S, Zeng G . Molecular Mechanism of MiR-136-5p Targeting NF-κB/A20 in the IL-17-Mediated Inflammatory Response after Spinal Cord Injury. Cell Physiol Biochem. 2017; 44(3):1224-1241. DOI: 10.1159/000485452. View

10.

Kickhoefer V, Rajavel K, Scheffer G, Dalton W, Scheper R, Rome L . Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem. 1998; 273(15):8971-4. DOI: 10.1074/jbc.273.15.8971. View

11.

Jemal A, Ward E, Johnson C, Cronin K, Ma J, Ryerson B . Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 2017; 109(9). PMC: 5409140. DOI: 10.1093/jnci/djx030. View

12.

Scheper R, Broxterman H, Scheffer G, Kaaijk P, Dalton W, van Heijningen T . Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993; 53(7):1475-9. View

13.

Gao D, Vahdat L, Wong S, Chang J, Mittal V . Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 2012; 72(19):4883-9. PMC: 3649848. DOI: 10.1158/0008-5472.CAN-12-1223. View

14.

Gupta G, Massague J . Cancer metastasis: building a framework. Cell. 2006; 127(4):679-95. DOI: 10.1016/j.cell.2006.11.001. View

15.

Furuta S, Jeng Y, Zhou L, Huang L, Kuhn I, Bissell M . IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med. 2011; 3(78):78ra31. PMC: 3199022. DOI: 10.1126/scitranslmed.3001374. View

16.

Yu M, Qi B, Xiaoxiang W, Xu J, Liu X . Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed Pharmacother. 2017; 90:677-685. DOI: 10.1016/j.biopha.2017.04.001. View

17.

Tan W, Liao Y, Qiu Y, Liu H, Tan D, Wu T . miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP). Cancer Lett. 2018; 428:55-68. DOI: 10.1016/j.canlet.2018.04.028. View

18.

Raaijmakers H, Izquierdo M, Lokhorst H, de Leeuw C, Belien J, Bloem A . Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood. 1998; 91(3):1029-36. View

19.

Huang C, Yang C, Jeng Y, Chen C, Wu H, Chang Y . Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-κB-mediated antiapoptotic pathway. Oncogene. 2013; 33(23):2968-77. DOI: 10.1038/onc.2013.268. View

20.

Abbondanza C, Rossi V, Roscigno A, Gallo L, Belsito A, Piluso G . Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell. J Cell Biol. 1998; 141(6):1301-10. PMC: 2132791. DOI: 10.1083/jcb.141.6.1301. View